Detalhe da pesquisa
1.
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Invest New Drugs
; 38(3): 844-854, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31385109
2.
Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients.
Histopathology
; 76(7): 976-987, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31994214
3.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345627
4.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol
; 18(9): 1202-1210, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729151
5.
A Cup of Coffee.
N Engl J Med
; 379(4): 312-313, 2018 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30044929
6.
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Histopathology
; 69(1): 25-34, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26588661
7.
Impact of a novel breast cancer survivorship program on patient-centered outcomes: A single institutional study.
Breast J
; 26(7): 1466-1471, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32115822
8.
The Promise.
Ann Intern Med
; 171(3): 218-219, 2019 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31382286
9.
Our Faustian pact with the digital world.
Lancet Oncol
; 18(2): 171-172, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28214405
10.
Bereaved and aggrieved in the age of social media.
Lancet Oncol
; 18(8): 1008, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28759365
11.
Misunderstandings, mandatory biopsies, and conflicts of interests in clinical trials: a coercive cocktail?
Lancet Oncol
; 18(7): 851-852, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677563
12.
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.
Breast Cancer Res
; 13(2): R47, 2011 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21521526
13.
The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression.
Breast Cancer Res
; 13(1): R19, 2011 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21306611
14.
Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
Breast Cancer Res
; 13(1): R9, 2011 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-21255398
15.
Novel Clinician-Lead Intervention to Address Fear of Cancer Recurrence in Breast Cancer Survivors.
JCO Oncol Pract
; 17(6): e774-e784, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33571035
16.
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
Int J Cancer
; 126(5): 1121-31, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19685490
17.
Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
Int J Cancer
; 126(6): 1445-53, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19676041
18.
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype.
Histopathology
; 56(3): 286-96, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20459529
19.
Sentinel node biopsy for melanoma: The medical oncology perspective.
Aust Fam Physician
; 44(12): 875-6, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27505912
20.
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Clin Cancer Res
; 26(19): 5086-5091, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32605909